Osaka, Japan-based Shionogi has completed its $2 billion acquisition of IntraBio, paid in a lump sum, expanding its rare disease portfolio with AQNEURSA (levacetylleucine), a treatment for rare neurological disorders.
The transaction, first disclosed Oct. 5, gives Shionogi global intellectual property and commercialization rights to AQNEURSA. Shionogi’s New Jersey-based subsidiary acquired all outstanding shares of IntraBio.
AQNEURSA received FDA approval in 2024 and European approval in January 2026 for neurological manifestations of Niemann-Pick disease type C. In September 2026, the FDA also approved the drug as the first treatment for ataxia in patients with ataxia-telangiectasia.
The drug is under European Medicines Agency review for ataxia-telangiectasia and is being evaluated in a phase 3 trial for CACNA1A disorders.
Shionogi’s rare disease portfolio also includes RADICAVA ORS (edaravone), a treatment for amyotrophic lateral sclerosis, and clinical programs targeting Pompe disease, Fragile X syndrome and Jordan’s syndrome.